S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
OTCMKTS:EKTAY

Elekta AB (publ) Stock Forecast, Price & News

$14.02
-0.44 (-3.04 %)
(As of 01/25/2021 05:19 PM ET)
Add
Compare
Today's Range
$13.91
Now: $14.02
$14.02
50-Day Range
$12.74
MA: $13.34
$14.27
52-Week Range
$6.25
Now: $14.02
$14.51
Volume2,628 shs
Average Volume4,470 shs
Market Capitalization$5.36 billion
P/E Ratio39.37
Dividend Yield0.97%
Beta0.85
Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. The company offers radiotherapy treatment systems, such as Versa HD, a dose delivery accuracy system; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.
Elekta AB (publ) logo

MarketRank

Overall MarketRank

0.84 out of 5 stars

Medical Sector

1091st out of 1,922 stocks

Medical Laboratories Industry

24th out of 39 stocks

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:EKTAY
CUSIPN/A
CIKN/A
Phone46-8-587-254-00
Employees3,800
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.44 billion
Cash Flow$0.63 per share
Book Value$2.26 per share

Profitability

Miscellaneous

Market Cap$5.36 billion
Next Earnings Date1/28/2021 (Estimated)
OptionableNot Optionable
$14.02
-0.44 (-3.04 %)
(As of 01/25/2021 05:19 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EKTAY News and Ratings via Email

Sign-up to receive the latest news and ratings for EKTAY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Elekta AB (publ) (OTCMKTS:EKTAY) Frequently Asked Questions

How has Elekta AB (publ)'s stock price been impacted by Coronavirus (COVID-19)?

Elekta AB (publ)'s stock was trading at $9.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EKTAY shares have increased by 55.7% and is now trading at $14.46.
View which stocks have been most impacted by COVID-19
.

Is Elekta AB (publ) a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elekta AB (publ) in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Elekta AB (publ) stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EKTAY, but not buy additional shares or sell existing shares.
View analyst ratings for Elekta AB (publ)
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Elekta AB (publ)?

Wall Street analysts have given Elekta AB (publ) a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Elekta AB (publ) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Elekta AB (publ)'s next earnings date?

Elekta AB (publ) is scheduled to release its next quarterly earnings announcement on Thursday, January 28th 2021.
View our earnings forecast for Elekta AB (publ)
.

How often does Elekta AB (publ) pay dividends? What is the dividend yield for Elekta AB (publ)?

Elekta AB (publ) announced a Semi-Annual dividend on Tuesday, July 21st. Shareholders of record on Friday, August 28th will be paid a dividend of $0.069 per share on Thursday, September 17th. The ex-dividend date is Thursday, August 27th. This is an increase from Elekta AB (publ)'s previous Semi-Annual dividend of $0.05.
View Elekta AB (publ)'s dividend history
.

Is Elekta AB (publ) a good dividend stock?

Elekta AB (publ) pays an annual dividend of $0.14 per share and currently has a dividend yield of 0.97%.
View Elekta AB (publ)'s dividend history.

Are investors shorting Elekta AB (publ)?

Elekta AB (publ) saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 2,400 shares, an increase of 200.0% from the December 15th total of 800 shares. Based on an average trading volume of 4,700 shares, the short-interest ratio is currently 0.5 days.
View Elekta AB (publ)'s Short Interest
.

Who are some of Elekta AB (publ)'s key competitors?

Who are Elekta AB (publ)'s key executives?

Elekta AB (publ)'s management team includes the following people:
  • Dr. Laurent Leksell, Founder & Chairman (Age 68)
  • Mr. Gustaf Salford, Pres & CEO (Age 43)
  • Mr. Johan Adeback, Group Treasurer & Acting CFO (Age 56)
  • Cecilia Ketels, Head of Investor Relations
  • Mr. Jonas Bolander, Gen. Counsel, Sec. & Exec. VP (Age 54)
  • Mr. Mattias Thorsson, Head of Corp. Communications & Public Affairs
  • Mr. Ioannis Panagiotelis, Exec. VP of APAC, Japan & South America and Chief Marketing & Sales Officer (Age 48)
  • Ms. Karin Svenske Nyberg, Exec. VP of HR (Age 54)
  • Mr. James P. Hoey, Head of External Relations (Age 62)
  • Mr. John Lapré, Pres of Brachy Solutions (Age 56)

What is Elekta AB (publ)'s stock symbol?

Elekta AB (publ) trades on the OTCMKTS under the ticker symbol "EKTAY."

How do I buy shares of Elekta AB (publ)?

Shares of EKTAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Elekta AB (publ)'s stock price today?

One share of EKTAY stock can currently be purchased for approximately $14.46.

How big of a company is Elekta AB (publ)?

Elekta AB (publ) has a market capitalization of $5.52 billion and generates $1.44 billion in revenue each year. Elekta AB (publ) employs 3,800 workers across the globe.

What is Elekta AB (publ)'s official website?

The official website for Elekta AB (publ) is www.elekta.com.

How can I contact Elekta AB (publ)?

Elekta AB (publ)'s mailing address is P.O. Box 7593, Stockholm V7, SE-103 93. The company can be reached via phone at 46-8-587-254-00 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.